Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 541 to 550 of 2440 total matches.
In Brief: Tegaserod (Zelnorm) Returns
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
with tegaserod for 1-3 months, 13 (0.11%) had a confirmed
ischemic event compared to only 1 (0.01%) of more than ...
Tegaserod maleate (Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults <65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic cardiovascular events (including...
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
/mL 3, 10 mL vials
3 mL KwikPen2
1-2 hrs 4-8 hrs 12-24 hrs ▶ Intermediate-acting human insulin ...
View the Expanded Table: Some Available Insulins
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
of allergic rhinitis and allergic conjunctivitis
are reviewed separately.1
INTRANASAL CORTICOSTEROIDS ...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Ozenoxacin 1% Cream (Xepi) for Impetigo
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
Ozenoxacin 1% Cream (Xepi) for Impetigo ...
The FDA has approved a 1% cream formulation
of ozenoxacin (Xepi – Cutanea), a nonfluorinated
quinolone antibiotic, for treatment of impetigo caused
by Staphylococcus aureus or Streptococcus pyogenes
in patients ≥2 months old.
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
is available.1
Pronunciation Key
Eravacycline: er” a va sye’ kleen Xerava: zuh ra’ va
Summary: Eravacycline ...
Eravacycline (Xerava – Tetraphase), a new synthetic
tetracycline antibiotic, has been approved by the
FDA for IV treatment of complicated intra-abdominal
infections (cIAIs) in adults. Eravacycline is structurally
similar to tigecycline (Tygacil, and generics), a broad-spectrum
tetracycline approved by the FDA for IV
treatment of complicated skin and skin structure
infections, complicated intra-abdominal infections,
and community-acquired pneumonia. A higher rate
of mortality has been reported with use of tigecycline
compared to other antibacterial drugs; it should be
used only...
Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
The Medical Letter on Drugs and Therapeutics • Apr 08, 2019 (Issue 1569)
,
triiodothyronine, or lithium.1
Electroconvulsive therapy (ECT) is often effective
for treatment of severe ...
The FDA has approved esketamine (Spravato –
Janssen), an N-methyl-D-aspartate (NMDA) receptor
antagonist, for intranasal treatment (in conjunction
with an oral antidepressant) of adults with treatment-resistant
depression (TRD). This is the first FDA
approval for esketamine, which is the S-enantiomer
of the intravenous anesthetic ketamine (Ketalar,
and generics). In recent years, IV ketamine has been
increasingly used (off-label) for treatment of TRD.
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
such as erythromycin or clindamycin.1,2
For moderate to severe inflammatory acne that does
not respond to topical ...
Sarecycline (Seysara — Allergan), a new oral
tetracycline antibiotic, has been approved by the FDA
for once-daily treatment of inflammatory lesions of
non-nodular moderate to severe acne in patients ≥9
years old.
ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
ZTlido — A New Lidocaine Patch
for Postherpetic Neuralgia
A lidocaine 1.8% patch (ZTlido – Scilex ...
A lidocaine 1.8% patch (ZTlido – Scilex) has been
approved by the FDA for treatment of pain associated
with postherpetic neuralgia (PHN). A lidocaine 5%
patch (Lidoderm, and generics) was approved earlier
for the same indication and has been used off-label
for treatment of other types of localized pain. Both
of these patches are available only by prescription.
Lidocaine 4% patches (Aspercreme, IcyHot, and others)
are available over the counter for back, neck, shoulder,
and joint pain.
Sulfonamide Cross-Reactivity
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
of
sulfanilamide. Both antibacterial and nonantibacterial
sulfonamide drugs (see Table 1) contain a sulfonamide ...
A reader has questioned why the label for the COX-2
selective NSAID celecoxib (Celebrex, and generics),
which contains a sulfonamide moiety, states that it
is contraindicated for use in patients with an allergy
to sulfonamides, while the labels of some other
sulfonamide drugs recommend either caution or no
precautions at all. The concept of cross-reactivity
among sulfonamide drugs, particularly between
antibacterial and nonantibacterial sulfonamides, has
been controversial for many years.
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
. Pharmacologic
treatment has included off-label use of timed loop
diuretics and desmopressin.1,2
Table 1 ...
The FDA has approved a sublingual tablet (Nocdurna –
Ferring) and a nasal spray (Noctiva – Avadel) formulation
of desmopressin acetate for treatment of nocturia due to
nocturnal polyuria in adults who wake up ≥2 times per
night to void. Nocdurna and Noctiva are the first two
products to be approved in the US for this indication.
Higher-strength nasal spray and oral tablet formulations
of desmopressin (DDAVP, and others) have been available
for years for treatment of diabetes insipidus and primary
nocturnal enuresis (bedwetting in children). In 2007, the
indication for primary...